Amicus scraps a top rare disease drug after it flunks a pivotal test — and shares spike
Just two months after Amicus Therapeutics $FOLD got a rare reprieve from the FDA, clearing the path for a new marketing application for its lead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
